Logo
x

Search

Subscribe Now

Small Lymphocytic Lymphoma

TG Therapeutics Reports the US FDA's Acceptance of BLA for Ublituximab + Ukoniq (umbralisib) to Treat Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

TG Therapeutics Reports the US FDA's Acceptance of BLA for Ublituximab + Ukoniq (umbralisib) to Treat Chronic Lymphocytic Leukemia...

  • May 26, 2021
BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeiGene Reports Results of Brukinsa (zanubrutinib) in P-III Head-to-Head APSEN Trial for R/R Chronic Lymphocytic Leukemia or Small...

  • April 29, 2021
AbbVie's Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA's Approval- First CT Free Treatment for 1L+ CLL/SLL

AbbVie's Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA's Approval- First CT Free Treatment for 1L+ CLL/SLL

  • January 28, 2019
Verastem Oncology's Copiktra (duvelisib) Receives FDA Approval for r/r 2L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Verastem Oncology's Copiktra (duvelisib) Receives FDA Approval for r/r 2L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma...

  • September 24, 2018
BMS Reports the US FDA’s Acceptance of sBLA with Priority Review for Breyanzi (lisocabtagene maraleucel) to Treat Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    BMS Reports the US FDA’s Acceptance of sBLA with Priority Review for Breyanzi (lisocabtagene maraleucel) to Treat Chronic Lymphocy...

    • November 10, 2023
    Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

      Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leuke...

      • October 17, 2023
      Eli Lilly Published P-I/II Trial (BRUIN) Results of Pirtobrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the NEJM

        Eli Lilly Published P-I/II Trial (BRUIN) Results of Pirtobrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma...

        • July 7, 2023
        InnoCare Published P-II Study Results of Orelabrutinib in P-II Study for Cancers in American Journal of Hematology

          InnoCare Published P-II Study Results of Orelabrutinib in P-II Study for Cancers in American Journal of Hematology

          • February 7, 2023
          AstraZeneca’s Calquence (acalabrutinib) Receives the US FDA’s Approval for the Treatment of Blood Cancers

            AstraZeneca’s Calquence (acalabrutinib) Receives the US FDA’s Approval for the Treatment of Blood Cancers

            • August 5, 2022
            Ascentage Reports First Patient Dosing of Lisaftoclax (APG-2575) in P-II (APG2575CC201) Study for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

              Ascentage Reports First Patient Dosing of Lisaftoclax (APG-2575) in P-II (APG2575CC201) Study for Chronic Lymphocytic Leukemia/Sma...

              • March 15, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.